Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk (NYSE:NVO)'s shares are significantly overvalued, based on analysis shared by the American bank Jefferies in a note to clients. It said that, as ever, Novo delivered its 'usual polished performance' at its capital markets day earlier this week, but added "we struggle to justify the stock uptick".

Novo Nordisk shares overhyped? One investment bank certainly thinks they are overvalued

Ozempic maker Novo Nordisk on Thursday teased a potential successor to its blockbuster weight loss drug Wegovy, the latest in a line of next-generation obesity treatments in development as consumers flock to the powerful drugs and competitors including Eli Lilly, Pfizer and an array of startups close in to claim a share of the lucrative market.

Ozempic Maker's New Weight Loss Pill Beats Wegovy In Early Trial — What To Know About Novo Nordisk's Amycretin

Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the US, last year becoming Europe's most valuable listed company, ahead of LVMH.

Ozempic maker Novo Nordisk surges past Tesla with market value of $566B

Novo Nordisk revealed results from a phase 1 study of amycretin at an investor event on Thursday. Patients taking the experimental drug achieved an average weight loss of 13.1% after 12 weeks.

Why Novo Nordisk Stock Is Jumping Today (Hint: It's Not Because of Ozempic or Wegovy)

Novo Nordisk said on Thursday it expects Wegovy to be approved for sale in China this year and plans to soon launch the popular weight-loss drug in the largest Asian market with capped volumes.

Novo Nordisk expects China to approve Wegovy this year

Novo Nordisk's global obesity drug rollout will be dominated by its injectable medicines, while its oral version will be introduced later in higher priced markets, the company's Chief Executive Lars Fruergaard Jorgensen said on Thursday.

Novo's global obesity drug rollout to be dominated by injectable medicines, CEO says

Novo Nordisk A/S (NYSE:NVO) stock is gapping to record highs today, after the pharmaceutical company reported positive phase 1 trial results for its experimental weight-loss drug, amycretin.

Pharma Stock Hits Record High on Newest Weight-Loss Drug

The company said its new treatment for weight loss, called Amycretin, appeared even more effective than its popular Wegovy drug in trials.

Novo Nordisk Surges. It's on Track to Overtake Tesla's Market Cap.

The American depositary receipts (ADRs) of Novo Nordisk A/S (NVO) gained more than 8% in early trading Thursday after the Danish maker of Ozempic and Wegovy released promising data on an experimental daily pill aimed at treating obesity.

Wegovy Maker Novo Nordisk Stock Surges on Promising Trial of Obesity Pill Amycretin

Catalent

Novo Nordisk expects to close its acquisition of Catalent later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is seen falling in the coming years.

Novo Nordisk expects Catalent deal to close later this year

Novo Nordisk is now worth more than Elon Musk's electric vehicle giant Tesla, after shares of the Danish maker of Ozempic surged following the release of promising results for an oral weight loss treatment.

Ozempic Maker Novo Nordisk More Valuable Than Tesla

Novo Nordisk (NYSE: NVO ) stock is soaring higher on Thursday after the pharmaceutical company announced results from a weight loss drug clinical trial. The big news here is the company's oral weight loss drug amycretin producing 13.1% weight loss in patients after 12 weeks.

NVO Stock Alert: Novo Nordisk Pops on New Weight-Loss Drug

Novo Nordisk's stock hit a fresh record high as the Danish drugmaker held a capital-market day, presenting the next generation of drugs that have propelled it to becoming Europe's largest company by market capitalization.

Novo Nordisk's stock hits new record as it advances oral weight-loss drug

Novo Nordisk (NYSE:NVO) unveiled a potential game changer during its Capital Markets Day with data on experimental obesity pill amycredtin potentially outperforming blockbuster drug Wegovy. An early-stage test conducted over 12 weeks showed patients taking the pill lost 13% of their weight.

Novo Nordisk obesity pill results send shares to record high

Shares hit a record after the Danish pharmaceutical giant said the drug could be more effective than blockbuster Wegovy.

Novo Nordisk Surges After Early Trial Shows Promise of New Obesity Drug

Novo Nordisk stock jumped after the Danish giant said its experimental oral drug amycretin showed a 13.1% weight loss after 12 weeks in a phase 1 trial.

Novo Nordisk Jumps On Promising Results For New Weight-Loss Drug

Eli Lilly

Novo Nordisk shares climbed 5% on Thursday morning after the Danish pharmaceutical giant reported positive early trial data for a new weight loss drug.

Novo Nordisk shares jump 5% on promising weight loss trial results; Eli Lilly dips

Novo Nordisk will begin a Phase II trial of its highly anticipated experimental drug amycretin in the second half of the year with results due in early 2026, the company's head of research and development Martin Lange Holst said on Thursday.

Novo Nordisk to begin Phase II trial of experimental obesity drug amycretin in H2 2024

Novo Nordisk , maker of obesity drug Wegovy, on Thursday said it would present early-stage trial data for its highly anticipated pipeline drug, amycretin, for treatment of Type 2 diabetes.

Novo Nordisk to present early-stage trial data for new diabetes drug at investor meeting

Bagsværd, Denmark, 7 March 2024 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025.

Highlights to be presented at Novo Nordisk's Capital Markets Day 2024

Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.

Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success

A clinical trial of semaglutide studying its ability to prevent kidney disease-related events was published. The study met its primary endpoint, but many observers were expecting better results.

Why Novo Nordisk Stock Tumbled by Nearly 3% on Tuesday

ARM Holdings PLC

Arm Stock and Novo Nordisk stock topped this screen of leading global growth stocks. One of them is near a buy point.

U.S. Stocks Aren't The Only Game In Town: Arm, Novo Please Investors

Viking Therapeutics' weight loss candidate produced positive phase 2 results. The drug could eventually be a challenger to Novo Nordisk's Wegovy.

A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish drug giant hailed the headline results from its FLOW trial which reduced kidney disease progression, major adverse cardiovascular events and death by 24% compared to placebo.

News for Novo Nordisk Stock (NVO)